FindTrial
Sign In

SHR3162

DRUG6 trials

Sponsors

Atridia Pty Ltd., Jiangsu HengRui Medicine Co., Ltd., Fudan University

Conditions

Breast CancerCastration-resistant Prostate CancerHealthy Adult Male and Female VolunteersHealthy VolunteersMetastatic CancerNeoplasmProstate CancerSolid Tumor

Phase 1

A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors
CompletedNCT02759666
Atridia Pty Ltd.Neoplasm, Solid Tumors
Start: 2016-06-01End: 2019-04-26Updated: 2019-09-19
The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors
TerminatedNCT03182673
Jiangsu HengRui Medicine Co., Ltd.Solid Tumor
Start: 2017-07-24End: 2019-06-12Updated: 2022-09-01
A Trial of SHR3162 in Healthy Caucasian Volunteers
CompletedNCT04333134
Atridia Pty Ltd.Healthy Volunteers
Start: 2020-04-17End: 2020-06-30Updated: 2022-07-14
Study to Evaluate the Safety and Pharmacokinetics of Single-Dose Fluzoparib in Healthy Chinese Subjects
NCT04341077
Jiangsu HengRui Medicine Co., Ltd.Healthy Adult Male and Female Volunteers
Start: 2020-04-10End: 2020-10-20Target: 12Updated: 2020-04-10

Phase 2

A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC
TerminatedNCT04102124
Jiangsu HengRui Medicine Co., Ltd.Castration-resistant Prostate Cancer, Prostate Cancer
Start: 2019-04-08End: 2021-08-31Updated: 2025-06-24
Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer
NCT04355858
Fudan UniversityBreast Cancer, Metastatic Cancer
Start: 2020-05-01End: 2025-04-01Target: 319Updated: 2022-07-26

Related Papers

Abstract PO1-15-07: Subtyping-directed precision treatment refines traditional one-size-fits-all therapy in HR+/HER2- breast cancer: a sub-study of the MULAN umbrella trial
Cancer Research2024-05-02
A phase I study of SHR7390 plus camrelizumab in advanced/metastatic colorectal cancer.
Journal of Clinical Oncology2021-05-201 citations